Role of cannabinoid receptors in anxiety disorders

Cannabinoids and the Brain

Volumn , Issue , 2008, Pages 559-572

  Degroot, Aldemar ^a  

^a Astellas Pharma Global Development   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79960310358     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-74349-3_24     Document Type: Chapter

References (77)

1. Azad SC, Monory K, Marsicano G, Cravatt BF, Lutz B, Zieglgansberger W, Rammes G (2004) Circuitry for associative plasticity in the amygdala involves endocannabinoid signaling. J Neurosci 24:9953-9961.
2. Bari M, Battista N, Fezza F, Gasperi V, Maccarrone M (2006) New insights into endocannabinoid degradation and its therapeutic potential. Mini Rev Med Chem 6:257-268.
3. Berrendero F, Maldonado R (2002) Involvement of the opioid system in the anxiolytic-like effects induced by Delta9-tetrahydrocannabinol. Psychopharmacology 163:111-117.
4. Biscaia M, Marin S, Fernandez B, Marco EM, Rubio M, Guaza C, Ambrosio E, Viveros MP (2003) Chronic treatment with CP 55, 940 during the peri-adolescent period differentially affects the behavioural responses of male and female rats in adulthood. Psychopharmacology 170:301-308.
5. 1A receptors are involved in the anxiolytic effect of Delta9-tetrahydrocannabinol and AM 404, the anandamide transport inhibitor, in Sprague-Dawley rats. Eur J Pharmacol 555:156-163.
6. Chhatwal JP, Davis M, Maguschak KA, Ressler KJ (2005) Enhancing cannabinoid neurotransmission augments the extinction of conditioned fear. Neuropsychopharmacology 30:516-524.
7. Crippa JA, Zuardi AW, Garrido GE, Wichert-Ana L, Guarnieri R, Ferrari L, Azevedo-Marques PM, Hallak JE, McGuire PK, Filho Busatto G (2004) Effects of cannabidiol (CBD) on regional cerebral blood flow. Neuropsychopharmacology 29:417-426.
8. 1 receptors modulates anxiety in the shock-probe burying test. Eur J Neurosci 20:1059-1064.
9. Degroot A, Nomikos GG (2005) Fluoxetine disrupts the integration of anxiety and aversive memories. Neuropsychopharmacology 30:391-400.
10. Degroot A, Nomikos GG (2007) In vivo neurochemical effects induced by changes in endocannabinoid neurotransmission. Curr Opin Pharmacol 7:62-68.
11. Degroot A, Treit D (2002) Dorsal and ventral hippocampal cholinergic systems modulate anxiety in the plus-maze and shock-probe tests. Brain Res 949:60-70.
12. 1 receptor antagonism increases hippocampal acetylcholine release: Site and mechanism of action. Mol Pharmacol 70:1236-1245.
13. 1A receptor ligand, S15535, displays anxiolytic-like effects in the social interaction and Vogel models and suppresses dialysate levels of 5-HT in the dorsal hippocampus of freelymoving rats. A comparison with other anxiolytic agents. Psychopharmacology 152:55-66.
14. Gaetani S, Cuomo V, Piomelli D (2003) Anandamide hydrolysis: A new target for anti-anxiety drugs? Trends Mol Med 9:474-478.
15. Genn RF, Tucci S, Marco EM, Viveros MP, File SE (2004) Unconditioned and conditioned anxiogenic effects of the cannabinoid receptor agonist CP 55, 940 in the social interaction test. Pharmacol Biochem Behav 77:567-573.
16. Giuliani D, Ferrari F, Ottani A (2000) The cannabinoid agonist HU 210 modifies rat behavioural responses to novelty and stress. Pharmacol Res 41:45-51.
17. Gregg JM, Small EW, Moore R, Raft D, Toomey TC (1976) Emotional response to intravenous delta9tetrahydrocannabinol during oral surgery. J Oral Surg 34:301-313.
18. 1 receptor antagonist rimonabant in models of emotional reactivity in rodents. Biol Psychiatry 57:261-267.
19. Guimaraes FS, Chiaretti TM, Graeff FG, Zuardi AW (1990) Antianxiety effect of cannabidiol in the elevated plus-maze. Psychopharmacology 100:558-559.
20. Guimaraes FS, de Aguiar JC, Mechoulam R, Breuer A (1994) Anxiolytic effect of cannabidiol derivatives in the elevated plus-maze. Gen Pharmacol 25:161-164.
21. Gunnell D, Saperia J, Ashby D (2005) Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: Meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review. BMJ 330:385.
22. 1 cannabinoid receptor on anxiety. Eur J Neurosci 16:1395-1398.
23. 1-specific agents. Behav Pharmacol 15:299-304.
24. Haller J, Soproni K, Varga B, Nemeth B, Mikics E, Freund TF, Matyas F, Hajos N (2006) Correlated species differences in the effects of cannabinoid ligands on anxiety and on GABAergic/glutamatergic synaptic transmission. Sixteenth Annual Symposium on the Cannabinoids, ICRS, Tihany, Hungary.
25. 1 receptor agonist HU-210 following chronic stress. Eur J Pharmacol 499:291-295.
26. Hill MN, Gorzalka BB (2006) Increased sensitivity to restraint stress and novelty-induced emotionality following long-term, high dose cannabinoid exposure. Psychoneuroendocrinology 31:526-536.
27. Howlett AC (2005) Cannabinoid receptor signaling. Handb Exp Pharmacol 168:53-79.
28. Jiang W, Zhang Y, Xiao L, Van Cleemput J, Ji SP, Bai G, Zhang X (2005) Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- And antidepressantlike effects. J Clin Invest 115:3104-3116.
29. Jung KM, Mangieri R, Stapleton C, Kim J, Fegley D, Wallace M, Mackie K, Piomelli D (2005) Stimulation of endocannabinoid formation in brain slice cultures through activation of group I metabotropic glutamate receptors. Mol Pharmacol 68:1196-1202.
30. Kataoka Y, Shibata K, Miyazaki A, Inoue Y, Tominaga K, Koizumi S, Ueki S, Niwa M (1991) Involvement of the dorsal hippocampus in mediation of the antianxiety action of tandospirone, a 5-hydroxytryptamine1A agonistic anxiolytic. Neuropharmacology 30:475-480.
31. Kreitzer AC, Malenka RC (2005) Dopamine modulation of state-dependent endocannabinoid release and long-term depression in the striatum. J Neurosci 25:10537-10545.
32. MacLean KI, Littleton JM (1977) Environmental stress as a factor in the response of rat brain catecholamine metabolism to delta8-tetrahydrocannabinol. Eur J Pharmacol 41:171-182.
33. 2+-assisted metabotropic glutamate receptor subtype 1 to phospholipase Cbeta4 signaling cascade in the cerebellum. J Neurosci 25:6826-6835.
34. Manzanares J, Corchero J, Fuentes JA (1999) Opioid and cannabinoid receptor-mediated regulation of the increase in adrenocorticotropin hormone and corticosterone plasma concentrations induced by central administration of delta9-tetrahydrocannabinol in rats. Brain Res 839:173-179.
35. Marco EM, Perez-Alvarez L, Borcel E, Rubio M, Guaza C, Ambrosio E, File SE, Viveros MP (2004) Involvement of 5-HT1A receptors in behavioural effects of the cannabinoid receptor agonist CP 55, 940 in male rats. Behav Pharmacol 15:21-27.
36. Marin S, Marco E, Biscaia M, Fernandez B, Rubio M, Guaza C, Schmidhammer H, Viveros MP (2003) Involvement of the kappa-opioid receptor in the anxiogenic-like effect of CP 55, 940 in male rats. Pharmacol Biochem Behav 74:649-656.
37. Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG, Hermann H, Tang J, Hofmann C, Zieglgansberger W, Di Marzo V, Lutz B (2002) The endogenous cannabinoid system controls extinction of aversive memories. Nature 418:530-534.
38. 1 cannabinoid receptors in emotional behaviour. Psychopharmacology (Berl) 159:379-387.
39. 1A agonists by shock intensity. Pharmacol Biochem Behav 46:569-573.
40. Millan MJ (2003) The neurobiology and control of anxious states. Prog Neurobiol 70:83-244.
41. Moreira FA, Aguiar DC, Guimaraes FS (2006) Anxiolytic-like effect of cannabidiol in the rat Vogel conflict test. Prog Neuropsychopharmacol Biol Psychiatry 30:1466-1471.
42. Musty R (1984) Possible anxiolytic effects of cannabidiol. In: Agurell S, Dewey WL, Willette RE (eds.), The Cannabinoids: Chemical, Pharmacological and Therapeutic Aspects. New York: Academic Press, pp. 795-813.
43. Musty R, Conti LH, Mechoulam R (1984) Anxiolytic properties of cannabidiol. In: Harvey DJ (ed.), Marihuana 84: Proceedings of the Oxford Symposium on Cannabis. Oxford: IRL Press, pp. 713-719.
44. Nadulski T, Sporkert F, Schnelle M, Stadelmann AM, Roser P, Schefter T, Pragst F (2005) Simultaneous and sensitive analysis of THC, 11-OH-THC, THC-COOH, CBD, and CBN by GC-MS in plasma after oral application of small doses of THC and cannabis extract. J Anal Toxicol 29:782-789.
45. Naliboff BD, Rickles WH, Cohen MJ, Naimark RS (1976) Interactions of marijuana and induced stress: forearm blood flow, heart rate, and skin conductance. Psychophysiology 13:517-522.
46. 1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat. Neuroreport 8:491-496.
47. Ng LK, Lamprecht F, Williams RB, Kopin IJ (1973) Delta9-tetrahydrocannabinol and ethanol: differential effects on sympathetic activity in differing environmental setting. Science 180:1368-1369.
48. 2 receptors in the brain. Neuropsychobiology 54:231-246.
49. Onaivi ES, Green MR, Martin BR (1990) Pharmacological characterization of cannabinoids in the elevated plus maze. J Pharmacol Exp Ther 253:1002-1009.
50. Pamplona FA, Prediger RD, Pandolfo P, Takahashi RN (2006) The cannabinoid receptor agonist WIN 55, 212-2 facilitates the extinction of contextual fear memory and spatial memory in rats. Psychopharmacology 188:641-649.
51. Patel S, Hillard CJ (2006) Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling. J Pharmacol Exp Ther 318:304-311.
52. Patel S, Roelke CT, Rademacher DJ, Cullinan WE, Hillard CJ (2004) Endocannabinoid signaling negatively modulates stress-induced activation of the hypothalamic-pituitary-adrenal axis. Endocrinology 145:5431-5438.
53. Patel S, Cravatt BF, Hillard CJ (2005) Synergistic interactions between cannabinoids and environmental stress in the activation of the central amygdala. Neuropsychopharmacology 30:497-507.
54. 2 receptors. Pharmacol Ther 74:129-180.
55. Pertwee RG (2005) Pharmacological actions of cannabinoids. Handb Exp Pharmacol 168:1-51.
56. Petitet F, Donlan M, Michel A (2006) GPR55 as a new cannabinoid receptor: Still a long way to prove it. Chem Biol Drug Des 67:252-253.
57. Piomelli D, Tarzia G, Duranti A, Tontini A, Mor M, Compton TR, Dasse O, Monaghan EP, Parrott JA, Putman D (2006) Pharmacological profile of the selective FAAH inhibitor KDS- 4103 (URB597). CNS Drug Rev 12:21-38.
58. Rakhshan F, Day TA, Blakely RD, Barker EL (2000) Carrier-mediated uptake of the endogenous cannabinoid anandamide in RBL-2H3 cells. J Pharmacol Exp Ther 292:960-967.
59. Resstel LB, Joca SR, Moreira FA, Correa FM, Guimaraes FS (2006) Effects of cannabidiol and diazepam on behavioral and cardiovascular responses induced by contextual conditioned fear in rats. Behav Brain Res 172:294-298.
60. Rimonabant. New Drug Evaluation. Regional Drug & Therapeutic Centre (November 2006): No 78. Available at http://www.nyrdtc.nhs.uk/docs/nde/NDE-78-Rimonabant.pdf.
61. Rodgers RJ, Haller J, Halasz J, Mikics E (2003) 'One-trial sensitization' to the anxiolytic-like effects of cannabinoid receptor antagonist SR141716A in the mouse elevated plus-maze. Eur J Neurosci 17:1279-1286.
62. 1 receptor antagonist, in plus-maze-naive and plus-maze-experienced mice. Behav Pharmacol 16:405-413.
63. Rodriguez de Fonseca F, Rubio P, Menzaghi F, Merlo-Pich E, Rivier J, Koob GF, Navarro M (1996) Corticotropin-releasing factor (CRF) antagonist [D-Phe12, Nle21, 38, C alpha MeLeu37]CRF attenuates the acute actions of the highly potent cannabinoid receptor agonist HU-210 on defensive-withdrawal behavior in rats. J Pharmacol Exp Ther 276:56-64.
64. Rubino T, Sala M, Vigano D, Braida D, Castiglioni C, Limonta V, Guidali C, Realini N, Parolaro D (2007) Cellular mechanisms underlying the anxiolytic effect of low doses of peripheral delta9-tetrahydrocannabinol in rats. Neuropsychopharmacology 32:2036-2045.
65. 1a receptors. Neurochem Res 30:1037-1043.
66. Rutkowska M, Jamontt J, Gliniak H (2006) Effects of cannabinoids on the anxiety-like response in mice. Pharmacol Rep 58:200-206.
67. Schneider M, Drews E, Koch M (2005) Behavioral effects in adult rats of chronic prepubertal treatment with the cannabinoid receptor agonist WIN 55, 212-2. Behav Pharmacol 16:447-454.
68. Takahashi RN, Pamplona FA, Fernandes MS (2005) The cannabinoid antagonist SR141716A facilitates memory acquisition and consolidation in the mouse elevated T-maze. Neurosci Lett 380:270-275.
69. Tzavara ET, Wade M, Nomikos GG (2003) Biphasic effects of cannabinoids on acetylcholine release in the hippocampus: Site and mechanism of action. J Neurosci 23:9374-9384.
70. 1 receptors. Neuropharmacology 46:966-973.
71. Viveros MP, Marco EM, File SE (2005) Endocannabinoid system and stress and anxiety responses. Pharmacol Biochem Behav 81:331-342.
72. Watanabe K, Kayano Y, Matsunaga T, Yamamoto I, Yoshimura H (1996) Inhibition of anandamide amidase activity in mouse brain microsomes by cannabinoids. Biol Pharm Bull 19:1109-1111.
73. Weiser M, Noy S (2005) Interpreting the association between cannabis use and increased risk for schizophrenia. Dialogues Clin Neurosci 7:81-85.
74. 1 receptors in mood and anxiety disorders. Behav Pharmacol 16:315-331.
75. Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG (1982) Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology 76:245-250.
76. Zuardi AW, Cosme RA, Graeff FG, Guimareas FS (1993a) Effects of ipsapirone and cannabidiol on human experimental anxiety. J Psychopharmacol 7:82-88.
77. Zuardi AW, Guimaraes FS, Moreira AC (1993b) Effect of cannabidiol on plasma prolactin, growth hormone and cortisol in human volunteers. Braz J Med Biol Res 26:213-217.